Progression of aberrant methylation over time in 3 JMML patients
| Patient ID/gene . | Time point during clinical course . | Age at diagnosis (months) . | Age at relapse (months) . | |||
|---|---|---|---|---|---|---|
| At diagnosis . | In remission after 1st HSCT . | At relapse . | In remission after 2nd HSCT . | |||
| D155 | ||||||
| BMP4 | 31% | n/a | 28% | 7% | 63 | 75 |
| CALCA | 32% | n/a | 45% | 4% | ||
| CDKN2B | 46% | n/a | 38% | 3% | ||
| RARB | 11% | n/a | 10% | 0% | ||
| D003 | ||||||
| BMP4 | 7% | 12% | 18% | — | 4 | 49 |
| CALCA | 3% | 5% | 61% | — | ||
| CDKN2B | 1% | 2% | 4% | — | ||
| RARB | 2% | 0% | 16% | — | ||
| D098 | ||||||
| BMP4 | 13% | n/a | 8% | — | 7 | 42 |
| CALCA | 13% | n/a | 80% | — | ||
| CDKN2B | 4% | n/a | 2% | — | ||
| RARB | 0% | n/a | 33% | — | ||
| Patient ID/gene . | Time point during clinical course . | Age at diagnosis (months) . | Age at relapse (months) . | |||
|---|---|---|---|---|---|---|
| At diagnosis . | In remission after 1st HSCT . | At relapse . | In remission after 2nd HSCT . | |||
| D155 | ||||||
| BMP4 | 31% | n/a | 28% | 7% | 63 | 75 |
| CALCA | 32% | n/a | 45% | 4% | ||
| CDKN2B | 46% | n/a | 38% | 3% | ||
| RARB | 11% | n/a | 10% | 0% | ||
| D003 | ||||||
| BMP4 | 7% | 12% | 18% | — | 4 | 49 |
| CALCA | 3% | 5% | 61% | — | ||
| CDKN2B | 1% | 2% | 4% | — | ||
| RARB | 2% | 0% | 16% | — | ||
| D098 | ||||||
| BMP4 | 13% | n/a | 8% | — | 7 | 42 |
| CALCA | 13% | n/a | 80% | — | ||
| CDKN2B | 4% | n/a | 2% | — | ||
| RARB | 0% | n/a | 33% | — | ||
n/a indicates material not available; and —, patient did not undergo 2nd HSCT.